TY - JOUR
T1 - Exploring Nanocarriers as Treatment Modalities for Skin Cancer
AU - Adnan, Mohammad
AU - Akhter, Md Habban
AU - Afzal, Obaid
AU - Altamimi, Abdulmalik S. A.
AU - Ahmad, Irfan
AU - Alossaimi, Manal A.
AU - Jaremko, Mariusz
AU - Emwas, Abdul-Hamid M.
AU - Haider, Tanweer
AU - Haider, Md. Faheem
N1 - KAUST Repository Item: Exported on 2023-08-08
Acknowledgements: This research was funded by Deanship of Scientific Research at King Khalid University grant number [RGP.02/260/44]. The authors express their gratitude to the Deanship of Scientific Research at King Khalid University for funding this work through a Large Research Group Project under grant number RGP.02/260/44. The authors are very thankful to the Research and Development department, Integral University Lucknow, for providing the necessary facilities required for completing this review work.
PY - 2023/8/5
Y1 - 2023/8/5
N2 - Cancer is a progressive disease of multi-factorial origin that has risen worldwide, probably due to changes in lifestyle, food intake, and environmental changes as some of the reasons. Skin cancer can be classified into melanomas from melanocytes and nonmelanoma skin cancer (NMSC) from the epidermally-derived cell. Together it constitutes about 95% of skin cancer. Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) are creditworthy of 99% of NMSC due to the limited accessibility of conventional formulations in skin cancer cells of having multiple obstacles in treatment reply to this therapeutic regime. Despite this, it often encounters erratic bioavailability and absorption to the target. Nanoparticles developed through nanotechnology platforms could be the better topical skin cancer therapy option. To improve the topical delivery, the nano-sized delivery system is appropriate as it fuses with the cutaneous layer and fluidized membrane; thus, the deeper penetration of therapeutics could be possible to reach the target spot. This review briefly outlooks the various nanoparticle preparations, i.e., liposomes, niosomes, ethosomes, transferosomes, transethosomes, nanoemulsions, and nanoparticles technologies tested into skin cancer and impede their progress tend to concentrate in the skin layers. Nanocarriers have proved that they can considerably boost medication bioavailability, lowering the frequency of dosage and reducing the toxicity associated with high doses of the medication.
AB - Cancer is a progressive disease of multi-factorial origin that has risen worldwide, probably due to changes in lifestyle, food intake, and environmental changes as some of the reasons. Skin cancer can be classified into melanomas from melanocytes and nonmelanoma skin cancer (NMSC) from the epidermally-derived cell. Together it constitutes about 95% of skin cancer. Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) are creditworthy of 99% of NMSC due to the limited accessibility of conventional formulations in skin cancer cells of having multiple obstacles in treatment reply to this therapeutic regime. Despite this, it often encounters erratic bioavailability and absorption to the target. Nanoparticles developed through nanotechnology platforms could be the better topical skin cancer therapy option. To improve the topical delivery, the nano-sized delivery system is appropriate as it fuses with the cutaneous layer and fluidized membrane; thus, the deeper penetration of therapeutics could be possible to reach the target spot. This review briefly outlooks the various nanoparticle preparations, i.e., liposomes, niosomes, ethosomes, transferosomes, transethosomes, nanoemulsions, and nanoparticles technologies tested into skin cancer and impede their progress tend to concentrate in the skin layers. Nanocarriers have proved that they can considerably boost medication bioavailability, lowering the frequency of dosage and reducing the toxicity associated with high doses of the medication.
UR - http://hdl.handle.net/10754/693505
UR - https://www.mdpi.com/1420-3049/28/15/5905
U2 - 10.3390/molecules28155905
DO - 10.3390/molecules28155905
M3 - Article
C2 - 37570875
SN - 1420-3049
VL - 28
SP - 5905
JO - Molecules
JF - Molecules
IS - 15
ER -
